Correction to: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
Eur J Drug Metab Pharmacokinet
.
2022 May;47(3):441.
doi: 10.1007/s13318-022-00759-8.
Authors
Swan Lin
1
,
Jason Gong
2
,
George C Canas
3
,
Peter Winkle
4
,
Kathleen Pelletier
5
,
Robert R LaBadie
5
,
Katherine Ginman
5
,
Yazdi K Pithavala
6
Affiliations
1
Pfizer Inc., Global Product Development, San Diego, CA, USA.
[email protected]
.
2
Pfizer Inc., Global Product Development, New York, NY, USA.
3
Prism Research Inc., Prism Clinical Research, St. Paul, MN, USA.
4
Anaheim Clinical Trials, Orange, CA, USA.
5
Pfizer Inc., Global Product Development, Groton, CT, USA.
6
Pfizer Inc., Global Product Development, San Diego, CA, USA.
PMID:
35258796
PMCID:
PMC9050760
DOI:
10.1007/s13318-022-00759-8
No abstract available
Publication types
Published Erratum